European Biotech Acquisition (EBAC) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access EBAC Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how European Biotech Acquisition adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2022)
(Sep 30 2022) (Jun 30 2022) (Mar 31 2022) (Dec 31 2021)
Assets
Cash & cash equivalent0.31
Cash & Short-term Investments0.00
Prepaid Expense, Current AS0.05
Total Current Assets0.36
Other Assets, Noncurrent129.00
Total Assets129.75
Liabilities
Accounts Payable, Current AC0.36
Accrued Liabilities, Current AC0.40
Other Liabilities, Current0.00
Accrual for Taxes Other than Income Taxes, Current TA0.03
Total Current Liabilities0.80
Total Long-term Debt0.00
Derivative Liability, Noncurrent DE1.32
Other liabilities, Noncurrent6.43
Total Liabilities8.55
Stockholders' Equity
Common Stock Value0.00
Retained Earnings / Accumulated Deficit-8.06
Other Equity-129.26
Common Stockholder's Equity-137.32
Non-controlling interests & other129.26
Total Stockholder's Equity-8.06
Liabilities & Stockholder's Equity129.75
4 historic quarters locked

Sign in to unlock the full European Biotech Acquisition balance sheet history.

About European Biotech Acquisition Corp Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-23-051721

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License